



**Miravo Healthcare™ Announces  
Second Quarter 2021 Results Release Date and  
Conference Call Details**

Mississauga, Ontario, Canada – July 26, 2021 – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its second quarter 2021 financial results before markets open on Monday, August 9, 2021.

The Company will subsequently hold a conference call the same day, Monday, August 9, 2021 at 11:00 a.m. ET, hosted by Jesse Ledger, Miravo’s President & Chief Executive Officer and other senior management. A question-and-answer session will follow the corporate update.

**CONFERENCE CALL DETAILS**

DATE: Monday, August 9, 2021

TIME: 11:00 a.m. ET

DIAL-IN NUMBER: 416 764 8688 or 1 888 390 0546

TAPED REPLAY: 416 764 8677 or 1 888 390 0541 / REPLAY PASSCODE: 457561#

The audio webcast can be accessed at:

[https://produceredition.webcasts.com/starthere.jsp?ei=1470704&tp\\_key=267126102f](https://produceredition.webcasts.com/starthere.jsp?ei=1470704&tp_key=267126102f)

An archived replay of the webcast will be available by clicking the link above.

**About Miravo Healthcare**

Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit [www.miravohealthcare.com](http://www.miravohealthcare.com).

**FOR MORE INFORMATION, PLEASE CONTACT:**

Investor Relations

Stefan Eftychiou  
905 326 1888 ext 60  
[stefan@bristolir.com](mailto:stefan@bristolir.com)